Literature DB >> 16254699

The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage.

Wolfgang Brück1.   

Abstract

Multiple sclerosis is a chronic inflammatory demyelinating disease of the central nervous system manifested morphologically by inflammation, demyelination, axonal loss and gliosis. The inflammatory lesions are characterized by massive infiltration by a heterogeneous population of cellular and soluble mediators of the immune system, including T cells, B cells, macrophages and mi croglia, as well as a broad range of cytokines, chemokines, antibodies, complement and other toxic substances. The appearance of such lesions is associated with clinical relapses. Recent detailed immunopathological studies of early, acute lesions revealed profound heterogeneity in the patterns of demyelination and the factors of the immune system involved. During remission, resolution of inflammation is the main factor which leads to clinical improvement of patients. However, the immune system can play a beneficial role at this stage, promoting remyelination perhaps by production of growth factors such as BDNF. In contrast, the progressive irreversible neurological deficit in multiple sclerosis is associated with neurodegenerative processes resulting in axonal and neuronal loss. The mechanisms behind damage to axons in multiple sclerosis lesions are poorly understood. However, the close proximity of areas with prominent axonal loss and areas containing inflammatory infiltrates (e. g., T cells, macrophages) suggest that axonal damage is closely associated with inflammation. Different soluble or cellular mediators of the immune response have been shown to damage axons in experimental systems, and these may be responsible for neurodegeneration in human disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16254699     DOI: 10.1007/s00415-005-5002-7

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  28 in total

1.  Axonal changes in chronic demyelinated cervical spinal cord plaques.

Authors:  G Lovas; N Szilágyi; K Majtényi; M Palkovits; S Komoly
Journal:  Brain       Date:  2000-02       Impact factor: 13.501

2.  Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination.

Authors:  C Lucchinetti; W Brück; J Parisi; B Scheithauer; M Rodriguez; H Lassmann
Journal:  Ann Neurol       Date:  2000-06       Impact factor: 10.422

3.  Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions.

Authors:  J W Peterson; L Bö; S Mörk; A Chang; B D Trapp
Journal:  Ann Neurol       Date:  2001-09       Impact factor: 10.422

4.  Cutting edge: clonally restricted production of the neurotrophins brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune cells and Th1/Th2-polarized expression of their receptors.

Authors:  M Besser; R Wank
Journal:  J Immunol       Date:  1999-06-01       Impact factor: 5.422

5.  Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible.

Authors:  E J Redford; R Kapoor; K J Smith
Journal:  Brain       Date:  1997-12       Impact factor: 13.501

6.  BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?

Authors:  Christine Stadelmann; Martin Kerschensteiner; Thomas Misgeld; Wolfgang Brück; Reinhard Hohlfeld; Hans Lassmann
Journal:  Brain       Date:  2002-01       Impact factor: 13.501

7.  MHC class I-restricted killing of neurons by virus-specific CD8+ T lymphocytes is effected through the Fas/FasL, but not the perforin pathway,.

Authors:  I M Medana; A Gallimore; A Oxenius; M M Martinic; H Wekerle; H Neumann
Journal:  Eur J Immunol       Date:  2000-12       Impact factor: 5.532

8.  Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance.

Authors:  Frederik Barkhof; Wolfgang Bruck; Corline J A De Groot; Elisabeth Bergers; Sandra Hulshof; Jeroen Geurts; Chris H Polman; Paul van der Valk
Journal:  Arch Neurol       Date:  2003-08

Review 9.  Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases.

Authors:  Harald Neumann; Isabelle M Medana; Jan Bauer; Hans Lassmann
Journal:  Trends Neurosci       Date:  2002-06       Impact factor: 13.837

10.  Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?

Authors:  M Kerschensteiner; E Gallmeier; L Behrens; V V Leal; T Misgeld; W E Klinkert; R Kolbeck; E Hoppe; R L Oropeza-Wekerle; I Bartke; C Stadelmann; H Lassmann; H Wekerle; R Hohlfeld
Journal:  J Exp Med       Date:  1999-03-01       Impact factor: 14.307

View more
  78 in total

Review 1.  Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis.

Authors:  Ranjan Dutta; Bruce D Trapp
Journal:  Prog Neurobiol       Date:  2010-10-12       Impact factor: 11.685

2.  Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010.

Authors:  Stuart D Cook; Suhayl Dhib-Jalbut; Peter Dowling; Luca Durelli; Corey Ford; Gavin Giovannoni; June Halper; Colleen Harris; Joseph Herbert; David Li; John A Lincoln; Robert Lisak; Fred D Lublin; Claudia F Lucchinetti; Wayne Moore; Robert T Naismith; Carlos Oehninger; Jack Simon; Maria Pia Sormani
Journal:  Int J MS Care       Date:  2012

3.  Antigen-specific therapy promotes repair of myelin and axonal damage in established EAE.

Authors:  Chunhe Wang; Bruce G Gold; Laurie J Kaler; Xiaolin Yu; Michael E Afentoulis; Gregory G Burrows; Arthur A Vandenbark; Dennis N Bourdette; Halina Offner
Journal:  J Neurochem       Date:  2006-08-03       Impact factor: 5.372

4.  Soluble vascular endothelial growth factor (VEGF) receptor-1 inhibits migration of human monocytic THP-1 cells in response to VEGF.

Authors:  Cansheng Zhu; Zhaojun Xiong; Xiaohong Chen; Zhengqi Lu; Guoyu Zhou; Dunjing Wang; Jian Bao; Xueqiang Hu
Journal:  Inflamm Res       Date:  2011-04-13       Impact factor: 4.575

5.  A critical role for virus-specific CD8(+) CTLs in protection from Theiler's virus-induced demyelination in disease-susceptible SJL mice.

Authors:  Meghann Teague Getts; Maureen H Richards; Stephen D Miller
Journal:  Virology       Date:  2010-04-08       Impact factor: 3.616

6.  Evaluation of serum levels of chemokines during interferon-β treatment in multiple sclerosis patients: a 1-year, observational cohort study.

Authors:  Elizabeth R Comini-Frota; Antonio L Teixeira; Janaína P A Angelo; Marcus V Andrade; Doralina G Brum; Damacio R Kaimen-Maciel; Norma T Foss; Eduardo A Donadi
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

Review 7.  The emerging roles of β-arrestins in fibrotic diseases.

Authors:  Yuan-jing Gu; Wu-yi Sun; Sen Zhang; Jing-jing Wu; Wei Wei
Journal:  Acta Pharmacol Sin       Date:  2015-09-21       Impact factor: 6.150

8.  Retinal pathology in multiple sclerosis: insight into the mechanisms of neuronal pathology.

Authors:  Peter A Calabresi; Laura J Balcer; Elliot M Frohman
Journal:  Brain       Date:  2010-06       Impact factor: 13.501

Review 9.  Chemokines as pain mediators and modulators.

Authors:  Fletcher A White; Natalie M Wilson
Journal:  Curr Opin Anaesthesiol       Date:  2008-10       Impact factor: 2.706

10.  HDAC1 nuclear export induced by pathological conditions is essential for the onset of axonal damage.

Authors:  Jin Young Kim; Siming Shen; Karen Dietz; Ye He; Owain Howell; Richard Reynolds; Patrizia Casaccia
Journal:  Nat Neurosci       Date:  2009-12-27       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.